Boston Scientific (BSX) Revenue — Quarter Ended Mar 31, 2023
Revenue increased in the current quarter compared to the prior quarter. The growth was also positive when measured against the same quarter one year earlier.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue increased in the current quarter compared to the prior quarter. The growth was also positive when measured against the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.4B
Revenue reported for this quarter.
Quarter-over-quarter
+4.5%
Change from the immediately preceding quarter.
Year-over-year
+12.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$13B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $3.2B | +5.4% |
| Sep 30, 2022 | $3.2B | +8.1% |
| Dec 31, 2022 | $3.2B | +3.7% |
| Mar 31, 2023 | $3.4B | +12.0% |
Revenue performance
The reported revenue direction is upward, with a sequential increase from the immediately preceding quarter. The year-over-year comparison also shows a rise.
Quarterly comparison
Compared to the immediately preceding quarter, revenue improved. Relative to the same quarter one year earlier, revenue was higher.
What to watch
The filing context mentions foreign currency fluctuations negatively impacted operational net sales growth in the Endoscopy segment.